Impact of body mass index on the prognosis of unresectable HCC patients receiving first‐line Lenvatinib or atezolizumab plus bevacizumab
Liver International · 2024
DOI: 10.1111/liv.15885 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Liver International, 2024. Verfasst von Margherita Rimini und 59 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Carcinoma, Hepatocellular, Liver Neoplasms, Phenylurea Compounds. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 45 Literaturangaben.
Abstract (Originalsprache)
Introduction
Overweight is a negative prognostic factor in the general population in the long term. However, the role of body mass index (BMI) in the short‐mid term in advanced tumours is unclear. The present analysis investigates the role of BMI weight classes in a large sample of patients affected by HCC and receiving atezolizumab plus bevacizumab or lenvatinib as first‐line treatment. Methods and Material The cohort included consecutive patients affected by BCLC‐c and BCLC‐B HCC patients from a multicenter international study group who received atezolizumab plus bevacizumab or lenvatinib as first‐line therapy. Population was stratified according to the BMI in under‐, over‐ and normal‐weight according to the conventional thresholds. The primary objective of the study was to evaluate the prognostic and predictive impact of BMI in patients affected by advanced or intermediate HCC. Survival curves were estimated using the product‐limit method of Kaplan–Meier. The role of stratification factors was analysed with log‐rank tests.
Results
1292 consecutive patients with HCC were analysed. 466 (36%) patients were treated with lenvatinib and 826 (64%) patients were treated with atezolizumab plus bevacizumab. In the atezolizumab plus bevacizumab arm, 510 (62%) patients were normal‐weight, 52 (6%) underweight and 264 (32%) overweight. At the univariate analysis for OS, underweight patients had significantly shorter OS compared to normal‐weight patients, whereas no differences were found between normal‐weight versus overweight. Multivariate analysis confirmed that underweight patients had significantly shorter OS compared to normal‐weight patients (HR: 1.7; 95% CI: 1.0–2.8; p = .0323). In the lenvatinib arm, 26 patients (5.6%) were categorized as underweight, 256 (54.9%) as normal‐weight, and 184 (39.5%) as overweight. At the univariate analysis for OS, no significant differences were found between normal‐weight versus underweight and between normal‐weight versus overweight, which was confirmed at multivariate analysis.
Conclusion
Our analysis highlighted a prognostic role of BMI in a cohort of patients with advanced HCC who received atezolizumab plus bevacizumab, while no prognostic role for low BMI was apparent in patients who received lenvatinib.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy.
- Vita-Salute San Raffaele University, Milan, Italy.
- Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
- Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
- Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan.
- Department of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan.
ORCID-Profile: Margherita Rimini, Bernardo Stefanini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Fabian Finkelmeier, Massimo Iavarone, Fabio Marra, Francesco Tovoli, Takashi Kumada, Masanori Atsukawa, Kazuto Tajiri, Satoshi Yasuda, Hidenori Toyoda, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita
Zitieren
APA
Rimini, M., Stefanini, B., Tada, T., Suda, G., Shimose, S., Kudo, M., Finkelmeier, F., Yoo, C., Presa, J., Amadeo, E., Genovesi, V., De Grandis, M. C., Iavarone, M., Marra, F., Foschi, F., Tamburini, E., Rossari, F., Vitiello, F., Bartalini, L., …, & Nagano, T. (2024). Impact of body mass index on the prognosis of unresectable HCC patients receiving first‐line Lenvatinib or atezolizumab plus bevacizumab. Liver International. https://doi.org/10.1111/liv.15885
Vancouver
Rimini M, Stefanini B, Tada T, Suda G, Shimose S, Kudo M, et al. Impact of body mass index on the prognosis of unresectable HCC patients receiving first‐line Lenvatinib or atezolizumab plus bevacizumab. Liver International. 2024. doi:10.1111/liv.15885
BibTeX
@article{Rimini2024,
author = {Rimini, Margherita and Stefanini, Bernardo and Tada, Toshifumi and Suda, Goki and Shimose, Shigeo and Kudo, Masatoshi and Finkelmeier, Fabian and Yoo, Changhoon and Presa, José and Amadeo, Elisabeth and Genovesi, Virginia and De Grandis, Maria Caterina and Iavarone, Massimo and Marra, Fabio and Foschi, Francesco and Tamburini, Emiliano and Rossari, Federico and Vitiello, Francesco and Bartalini, Linda and Soldà, Caterina and Tovoli, Francesco and Vivaldi, Caterina and Lonardi, Sara and Silletta, Marianna and Kumada, Takashi and Sakamoto, Naoya and Iwamoto, Hideki and Aoki, Tomoko and Himmelsbach, Vera and Montes, Margarida and Hiraoka, Atsushi and Sho, Takuya and Niizeki, Takashi and Nishida, Naoshi and Steup, Christoph and Hirooka, Masashi and Kariyama, Kazuya and Tani, Joji and Atsukawa, Masanori and Takaguchi, Koichi and Itobayashi, Ei and Fukunishi, Shinya and Tsuji, Kunihiko and Ishikawa, Toru and Tajiri, Kazuto and Ochi, Hironori and Yasuda, Satoshi and Toyoda, Hidenori and Ogawa, Chikara and Nishimura, Takashi and Hatanaka, Takeshi and Kakizaki, Satoru and Shimada, Noritomo and Kawata, Kazuhito and Tada, Fujimasa and Ohama, Hideko and Nouso, Kazuhiro and Morishita, Asahiro and Tsutsui, Akemi and Nagano, Takuya},
title = {Impact of body mass index on the prognosis of unresectable HCC patients receiving first‐line Lenvatinib or atezolizumab plus bevacizumab},
journal = {Liver International},
year = {2024},
doi = {10.1111/liv.15885}
}
EUVIMED